Program
Zocilurtatug Pelitecan
Also written as “ZL-1310” and “ZL-1310 in combination with Atezolizumab or Durvalumab”.
Its studies are mostly in Small Cell Lung Carcinoma, led by 3 companies.
Drug pageZocilurtatug Pelitecan: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Zai Labits history only | 44 open or running | phase 3since Oct 8, 2025 | Dec 7, 2023 | May 30, 2027phase 1 · NCT06179069 |
| Amgen | 11 open or running | phase 1since Apr 9, 2026 | Apr 9, 2026 | May 21, 2028phase 1 · NCT07531095 |
| Boehringer Ingelheimits history only | 11 open or running | phase 2since Jul 13, 2026 | Jul 13, 2026 | Apr 26, 2030phase 2 · NCT07707895 |
Also a collaborator on its studies: Zai Lab (US).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Amgen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jan 29, 2026Named zocilurtatug pelitecanINNProposed as its International Nonproprietary Name in WHO's List 134 · before, ZL-1310
- Apr 9, 2026First study: phase 1 study in Small Cell Lung CarcinomaFirst studyNCT07531095 · 160 planned · United States, Australia, Belgium and more
Ahead
- May 21, 2028Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT07531095
TargetBeta
“An antibody-drug conjugate (ADC) composed of zocilurtatug, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) and ”NCIt, by rule
Other programs on DLL3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tarlatamabrule | Amgen | phase 3 | 13 |
| Alveltamigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 11 |
| obrixtamig | Boehringer Ingelheim | phase 3 | 11 |
| Anti-DLL3 Antibody-drug Conjugate BL-M14D1 | Sichuan Biokin Pharmaceutical | phase 3 | 4 |
| gocatamig | Merck | phase 3 | 4 |
| Autologous Anti-DLL3 CAR-T Cells DJI136 | Novartis | phase 2 | 2 |
| Anti-DLL3 Antibody-drug Conjugate IDE849 | ideaya-biosciences | phase 2 | 2 |
| SHR-7787 | Jiangsu HengRui Medicine | phase 2 | 1 |
| Anti-DLL3 Antibody-drug Conjugate FZ-AD005rule | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical | phase 1 | 2 |
| clesitamig | Hoffmann-La Roche | phase 1 | 2 |
| Actinium Ac 225-ABD147rule | abdera-therapeutics-inc | phase 1 | 1 |
| Indium In 111-ETN029 | Novartis | phase 1 | 1 |
Studies
The one study Amgen leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07531095Small Cell Lung Carcinoma · United States, Australia, Belgium and more | 1 | Recruiting | May 21, 2028 | 160 |
How it is read
Names in the registry
- “ZL-1310”, 5 entries
- “ZL-1310 in combination with Atezolizumab or Durvalumab”, 1 entry
Codes read as this program: ZL1310.
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.